SynthesisNeurosurgical review2025
Influence of supratotal resection on overall survival and progression of tumor in gliomas grade 2 and 3: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence after resection is a major factor in poor prognosis for grade 2 and 3 gliomas. The effect of Supratotal Resection (STR) on recurrence timing remains debated. This meta-analysis examines overall survival (OS) and tumor progression in grade 2 and 3 gliomas after supratotal resection.
methodsStudies on patients with grade II and III gliomas who underwent supratotal resection were included, with comparisons to subtotal, partial, and total resections. The primary outcomes were overall survival (OS) and tumor progression, while secondary outcomes included return-to-work (RTW) rates, malignant transformations and cognitive impairments.
resultsWe included 954 patients from 8 studies, mean age was 39 (± 16) years. The mean OS for patients undergoing supratotal resection was 17.45 (95% CI: 3.39 to 89.74, p < 0.05) compared to TR. The OR for RTW in the STR group versus TR group was 0.12 (95% CI: 0.01 to 1.28, p = 0.08). Tumor progression OR was, no statistical significantly, 0.15 (95% CI: 0.00 to 38.00, p = 0.5), and the likelihood of malignancy was reduced 0.03 (95% CI: 0.01 to 0.18, p < 0.01) compared to the TR group. In the immediate pos-operatory, when comparing STR with TR, the OR of language impairment was 5.47 (95% CI: 2.73 to 10.97, p < 0.01) and cognitive impairment was 0.38 (95% CI: 0.17 to 0.58). During the follow-up, the OR of language impairment was 0.68 (95% CI: 0.25 to 1.81, p = 0.44) and cognitive impairment was 0.34 (95% CI: 0.03 to 3.61, p = 0.37) comparing STR with TR.
conclusionPatients with grade 2 and 3 gliomas undergoing supratotal resection showed significantly higher overall survival, fewer malignant transformations and language impairments in immediate pos-operatory. While there was a trend towards higher return-to-work rates, progression of tumor and better cognitive status during the follow-up, it was not statistically significant. Further studies are needed for definitive conclusions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
40032671What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.